BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, has announced that it has launched a Regulation A+ (Mini-IPO) following the validation of its Form 1-A offering circular by the U.S. Securities and Exchange Commission. The purpose of this offering is to allow both accredited and non-accredited potential investors the opportunity to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market.
The BIOLIFE4D bioprinted organ replacement process begins with a magnetic resonance imaging (MRI) procedure used to create a detailed three-dimensional image of a patient’s heart. Using this image, a computer software program will construct a digital model of a new heart for the patient, matching the shape and size of the original. Doctors safely take cells from the patient via a blood sample, and leveraging recent stem cell research breakthroughs, BIOLIFE4D plans to reprogram those blood cells and convert them to create specialized heart cells.
Bioprinting is done with a 3D bioprinter that is fed the dimensions obtained from the MRI. After printing, the heart is then matured in a bioreactor, conditioned to make it stronger and readied for patient transplant.